Clinical and bacteriological efficacy of amikacin in the treatment of lower urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli or Klebsiella pneumoniae

Antibiotic Susceptibilities and Genetic Characteristics of Extended-Spectrum Beta-Lactamase-Producing <i>Escherichia coli</i> Isolates from Stools of Pediatric Diarrhea Patients in Surabaya, Indonesia

“…Current antibiotic susceptibilities were not apparently worse than previously described, suggesting that the risks associated with ESBL-producing E. coli have not changed in eastern Indonesia between 2005 and 2012; this information is critical in both the medical and governmental settings. ESBL-producing E. coli have shown good susceptibilities only to carbapenems and AMK (26,27); this is largely in agreement with our data showing good susceptibilities of ESBL producers to carbapenems (IPM), AMK, and FOM. Taken together with our antibiotic susceptibility results for strains with ST617, the data indicate that these 3 antibiotics have good activity against ESBL producers, even in strains with ST617, which is associated with high resistance potential.…”

The Urinary System Infections caused by Extended-Spectrum-β-Lactamase-producing Escherichia coli and Klebsiella pneumoniae Strains

“…In multicenter studies, the rates of ESBL-producing bacteria vary between 1-74% depending on the countries and regions (3,10,11). In Turkey, however, the rates of ESBL-positive E. coli and K. pneumoniae strains have been reported between 21-29% and 35-49%, respectively (5,(12)(13)(14). In our study, we found the rates for E. coli and K. pneumoniae as 39.6% and 44.8%, respectively, which revealed that the rate for E. coli strains was higher than the ones reported for Turkey.…”

“…In our study, although no resistance was observed against imipenem and meropenem in E. coli and K. pneumoniae strains, the resistance rate of ertapenem was assessed as 1.9% and 3.8%, respectively. Amikacin is the second most active antibiotic following Carbapenems (12,18). In our study, the resistance rates of Amikacin in ESBL-positive E. coli and K. pneumoniae strains were 13.2% and 3.8%, respectively.…”

The rates of quinolone, trimethoprim/sulfamethoxazole and aminoglycoside resistance among Enterobacteriaceae isolated from urinary tract infections in Azerbaijan, Iran

“…It is known that single daily dose aminoglycoside usage reduces their complication and increases the antibacterial effect. In a study carried out by Ipekci et al [27], nephrotoxicity was only reported in 2.8% of all the patients with a single daily dose of amikacin. …”